ArticleHead and neck pathology2026
Clinical and Prognostic Factors of Submandibular Gland Malignancies: A SEER-Based Analysis : Analysis of Submandibular Gland Tumors.
Article in Head and neck pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWhile neoplasms of the submandibular gland (SMG) are rare, there is a nearly 50% risk of malignancy and its neoplasms are associated with poorer prognoses. Due to the rarity of these tumors, clinical and prognostic information relating to these tumors is limited; we aimed to elucidate these factors using an analysis of the Surveillance, Epidemiology, and End Results (SEER) database.
methodsA retrospective population-based analysis was performed with data regarding primary SMG malignancy from 2000 to 2019 as extracted from the SEER database. Kaplan-Meier curves and log-rank tests assessed differences in survival by tumor grade and treatment. To estimate odds of death, Royston-Parmar Proportional Odds models were used. Stratified analyses were conducted by tumor stage and histology subtype.
resultsData from 2875 patients were extracted. Kaplan-Meier analyses on a sample of 2809 patients showed survival differing significantly by tumor grade, histologic subtype, and treatment (p < 0.0001). Most favorable survival outcomes were amongst mucoepidermoid neoplasms, ductal and lobular neoplasms, and adenocarcinomas, and least favorable survival outcomes amongst epithelial and squamous cell neoplasms. Surgery alone and with adjuvant radiation and chemoradiotherapy both showed significantly lower odds of death for the overall sample.
conclusionMulti-variate analysis indicated significantly lower odds of death with treatments involving surgery, while no significant differences were seen for radiation and chemoradiotherapy alone, likely due to the latter patients being poor surgical candidates or with advanced metastatic disease. Optimal treatment modalities for SMG malignancies are still being determined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.